ArticleAlpha psychiatry2025
Clinical Patterns of Dyslipidemia in Patients With Initial-Treatment and Drug-Naïve Schizophrenia.
Article in Alpha psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia (SCZ) is a common, chronic, severe mental disorder that is often accompanied by dyslipidemia and linked to decreased life expectancy. The prevalence of dyslipidemia among initial-treatment and drug-naïve (ITDN) patients with SCZ and the correlates influencing its occurrence and severity were determined in this study. Methods: Demographic and clinical data including blood pressure, blood cell count, renal function, lipid profile, fasting glucose level, and thyroid function were collected from the 668 patients with ITDN SCZ included in this study. Psychopathology and illness severity were evaluated using the Positive and Negative Symptom Scale and the Clinical Global Impression Scale - Severity of Illness, respectively. Results: The prevalence of dyslipidemia was 33.53% (224/668) and the influencing factors included higher education attainment (B = 0.43, Conclusions: Our study provides valuable insights into the clinical characteristics of dyslipidemia in ITDN SCZ patients. The identified factors influencing dyslipidemia occurrence and severity could serve as potential bioindicators for its prevention and intervention in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.